ISSUE 9/2025

BDMAI Bulletin

From the Desk of President

Dear Friends,

It gives me immense pleasure to invite you to the **Annual General Meeting of BDMAI**, scheduled to be held on 18th September 2025 at 6:30 p.m. at Hotel ITC Grand Kakatiya, Hyderabad.

We are honoured to have **Sri G. V. Prasad**, Co-Chairman and Managing Director of Dr. Reddy's Laboratories, who has kindly consented to grace the occasion. He will be sharing his invaluable insights and experiences on various industry-related topics during an engaging Fireside Chat. I am sure you would not want to miss the opportunity to hear from one of the most respected leaders in our industry.

In today's rapidly changing world, adopting **Green Chemistry** and embracing **new energy technologies** has become imperative. In line with this, we have organized two insightful presentations:

"Harnessing Solar – Advancing Pharma Industry" by Anor Sunshine
"Sustainable Energy Solutions for Pharma Industry" by Thermax

The General Secretary of BDMAI will also present a comprehensive report on the Association's activities over the past year.

More than just a formal meeting, I see this as an important occasion to come together as an industry — to share our experiences, discuss challenges, and explore collaborative opportunities. With our increasingly busy schedules, such in-person gatherings are rare but essential.

Let us take this opportunity to reconnect, reflect, and move forward together.

Looking forward to seeing you in person on 18th September 2025.
With best Regards,

R K Agrawal
National President

In this Beulletin you can expect:

Global Pharma News
New Drug Developments, Investments, Drug Approvals, M&As

BDMAI Activities
Representations
Meetings
Members
Achievements

Technical & Commercial Articles

Global Pharma News

Pfizer battles another Paxlovid lawsuit from Enanta

Pfizer says it is “confident” in the intellectual property for its billion-dollar Covid-19 pill Paxlovid. In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders.

Pharmaceutical Technologies 19.8.2025

MHRA pilot to prepare sponsors for clinical trial regulation changes

The Route B notification pilot will expand the MHRA’s risk-proportionate approach and help prepare for a new modifications process under upcoming regulations.

European Pharmaceutical Review 29.8.2025

M&A / Joint Ventures

Boehringer Ingelheim signs gene therapy manufacturing deal with AnGes

The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene. Boehringer Ingelheim’s BioXcellence contract development and manufacturing organisation (CDMO) has agreed a new deal with AnGes to supply the drug substance for its peripheral arterial disease treatment. AnGes recently completed the clinical trials programme for its Hepatocyte Growth Factor (HGF) gene therapy product Collategene and is preparing to submit its Biologics License Application to US regulators. The Tokyo-headquartered biopharmaceutical firm’s manufacturing

agreement builds on its existing collaboration with BioXcellence that has seen the CDMO's microbial technology in E. coli used to manufacture Collategene's active pharmaceutical ingredient (API).

Pharma Journalist 20.8.2025

ANGLE partners with Myriad Genetics to explore blood-based cancer testing

ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE's Parsortix system can be used alongside Myriad's existing tissue-based diagnostic assays. The project will see ANGLE's R&D team process blood samples from cancer patients with Parsortix, which captures intact cancer cells for downstream analysis. Results will then be compared with matched patient tissue samples using Myriad Genetics' established tissue assays.

Pharma Times 22.8.2025

Drug Approvals

PTC Therapeutics Gets FDA Complete Response Letter for Vatiquinone NDA

PTC Therapeutics, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for vatiquinone, a treatment candidate for Friedreich's ataxia in both children and adults.In the CRL, the FDA stated that substantial evidence of efficacy was not demonstrated, and that an additional well-controlled clinical trial would be required to support any future resubmission."We are of course disappointed by the FDA's decision," said Dr. Matthew B. Klein, CEO of PTC Therapeutics. "We believe the data collected to date show that vatiquinone could offer a safe and effective therapy for people living with Friedreich's ataxia. We intend to meet with the FDA to explore potential next steps."

Pharma Journalist 20.8.2025

Daiichi Sankyo and AstraZeneca's Datroway receives approval in China

Datroway's approval is based on results from the Phase III TROPION-Breast01 trial; Daiichi Sankyo and AstraZeneca have received approval from China's National Medical Products Administration (NMPA) for Datroway (datopotamab deruxtecan) to treat adult patients with unrespectable or metastatic hormone receptor (HR)

positive, HER2 negative breast cancer. This approval applies to patients who have previously undergone endocrine therapy and at least one line of chemotherapy in an advanced setting. The drug is a TROP2-directed antibody drug conjugate (ADC).

Pharmaceutical Technologies 25.8.2025

Cartherics granted Chinese patent for enhancing immune cell function

Cartherics, a biotech company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programs in ovarian cancer and endometriosis, has announced the granting of a patent for 'Method for Providing Immune Cells with Enhanced Function' by the Chinese Patent Office.

Pharmaceutical Manufacturer 27.8.2025

FDA tightens use of Pfizer, Moderna and Novavax COVID-19 vaccines

RFK Jr hits Comirnaty, Spikevax and Nuvaxovid with revised approvals for 'high risk' individuals.

The US Food and Drug Administration (FDA) has revoked its emergency COVID-19 vaccine approvals, handing out three revised mandates that mainly restrict use to those deemed 'high risk'.

European Pharmaceutical Review 29.8.2025

Lilly receives UK approval for pirtobrutinib in relapsed blood cancers

MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma

Eli Lilly and Company has received conditional marketing authorisation from the MHRA for pirtobrutinib (Jaypirca) as monotherapy for adults with relapsed or refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Pharma Times 1.9.2025

FDA Approves 3-Month Leuprolide Mesylate 21-mg Formulation for Advanced Prostate Cancer

The FDA approved the new drug application (NDA) for leuprolide mesylate 21 mg (Camcevi ETM; Foresee Pharmaceuticals), a ready-to-use long-acting injectable (LAI) formulation that is administered every 3 months as a treatment for advanced prostate cancer. Leuprolide mesylate 21 mg now joins the 6-month, 42-mg formulation of leuprolide mesylate as an FDA-approved treatment

for adults with advanced prostate cancer, which was previously approved in 2021.

Pharmacy Times 29.8.2025

New Drug Developments:

Late-stage trial boost for Argenx's myasthenia gravis drug Vyvgart

The Phase III findings could represent a critical advancement in managing the rare autoimmune disease in those with limited treatment options. Argenx SE's antibody drug Vyvgart has become the first myasthenia gravis treatment to improve disease activity across all three subtypes of the rare autoimmune disease in a late-stage trial. Argenx SE's antibody drug Vyvgart has become the first myasthenia gravis treatment to improve disease activity across all three subtypes of the rare autoimmune disease in a late-stage trial

Pharmatechnologies 18.8.2025

Four drugs race for first bispecific ADC approval

While 84% of products remain in early development, the four late-stage contenders are poised for regulatory approval in East Asia. Bispecific (bs) antibody drug conjugates (ADCs) are an emerging therapeutic approach that present advantages over traditional ADCs. With 84% of bsADCs in the preclinical or discovery stages, the pipeline is still nascent. But, with four candidates in Phase III, the race for the first approval in this novel landscape is underway.

Global Data Healthcare 28.8.2025

Teva brings first generic GLP-1 to US market with Saxenda copycat approval

Although Saxenda is the first generic GLP-1 to hit the US market, its sales will likely be overshadowed by next-gen drugs such as Wegovy and Zepbound. Generics company Teva Pharmaceutical has obtained approval from the US Food and Drug Administration (FDA) for its generic referencing Novo Nordisk's previous generation of injectable weight loss drug, Saxenda (liraglutide). This marks the first time a generic glucagon-like peptide-1 receptor agonist (GLP-1RA) medication has been approved for weight loss in the US.

European Pharmaceutical Manufacturer 1.9.2025

AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025

Topical TRPV1 antagonist shows promise in heat-induced neuropathic pain

AlzeCure Pharma has presented new clinical data on its lead pain candidate ACD440 at the NeuPSIG 2025 international pain conference. The presentation includes results from the phase 2 study in chronic peripheral neuropathic pain. ACD440 is a first-in-class TRPV1 antagonist developed as a topical gel for localised treatment. It is designed to minimise systemic exposure while maintaining high local concentrations for sustained analgesic effect. The drug originated in Big Pharma and is based on Nobel Prize-winning science.

Pharma Times 4.9.2025

Lilly's Olomorasib Gets FDA Breakthrough Therapy Nod for New Metastatic KRAS G12C Lung Cancer Treatment

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib, in combination with KEYTRUDA (pembrolizumab), for first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation and high PD-L1 expression.

Pharma Times 4.9.2025

Teva wins US obesity approval for its GLP-1 generic liraglutide

And Eli Lilly and Company's new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials. The obesity drug market continues to mature with US approval for the first generic version of a glucagon-like peptide (GLP)-1 drug that's indicated for weight loss. Alongside that the pharma industry keeps working on newer obesity drug candidates, with a new oral GLP-1 from Eli Lilly and Company posting strong Phase III data.

Pharma Journalist 5.9.205

Representations:

CDSCO - Issue of WHO GMP (CoPPs) through online system:

Subsequent to the issue of notification by CDSCO making it compulsory to apply for WHO GMP / CoPPs with effect from 15.8.2025, BDMAI organized a meeting on 4th Aug 2025 to discuss about the issues / concerns of members while applying for WHO GMP (CoPPs). Executives from Aurobindo, Hetero, Gland Pharma, Granules, Virchow, Natco, SMS Pharma, Laurus, MSN, Biophore etc. have attended. Issues / Concerns were compiled and submitted to CDSCO along with a representation. Please click here to see the detailed representation.

MoEF – Mandatory Use of Re-cycled Plastic

MoEF issued a notification draft 3rd June 2025, according to which all industries are required to use re-cycled plastic and sought inputs / objections within one month. BDMAI submitted a representation seeking exemption Bulk Drug industry from these rules as it is not allowed to use re-cycled plastic as per GMP rules. Please click here to see the detailed representation

DoP - Inclusion of Non-Scheduled Chemicals under Schedule A

BDMAI received communication from Department of Pharmaceuticals, Government of India, informing about the proposal of including Mono Methyl Amine and 2-Bromo-4-Methylpropiophenone under Schedule A of NDPS Act. BDMAI submitted a representation requesting the Government not to include them under Schedule A as they are used extensively in various industries. Please click here to see the detailed representation

Visit to Sparsh Hospice

Some of the Office Bearers of BDMAI are the Trustee of Sparsh Hospice, an initiative of Rotary Club, Banjara Hills branch. This Charitable Trust is a dedicated palliative care centre offering free pain and symptom management to terminally ill patients. At the request of Trustees, Executive Committee Meeting of BDMAI was organized at Sparsh Hospice. More details about this Centre are next page

Sainor Group of Companies

Generously donated Rs.25 (Twenty Five) Lakhs to Sparsh Hospice, an initiative of the Rotary Club of Banjara Hills Charitable Trust, is a dedicated palliative care center offering free pain and symptom management to terminally ill patients

Aragen Advances Renewable Energy Commitment with 7.69 MWp Group Captive Solar PPA

Aragen Life Sciences is pleased to announce the signing of a **7.69 MWp Group Captive Solar Power Purchase Agreement (PPA)** with **Radiance Renewables**.

This strategic initiative marks a significant milestone in our sustainability journey, aligning with our long-term vision of reducing carbon emissions and transitioning to clean energy. The project will contribute substantially to meeting Aragen's renewable energy targets, reducing dependency on conventional power sources, and lowering the company's carbon footprint. By adopting group captive solar power, Aragen strengthens its commitment to environmental stewardship while supporting India's renewable energy mission.

Sparsh Hospice

Sparsh Hospice – Ensuring dignity during end-of-life stages

About Sparsh:

Sparsh Hospice, an initiative of the Rotary Club of Banjara Hills Charitable Trust, is a dedicated palliative care center offering free pain and symptom management to terminally ill patients. Our services are delivered through a state-of-the-art in-patient and out-patient facility, six fully equipped homecare vans, and fortnightly OP clinics across two districts in Telangana. Over the past 14 years, we've brought comfort and dignity to 14,000+ patients and their families, easing suffering and offering compassionate support during life's most difficult moments. In 2011, the centre was started with 12 beds, at the time, when there was no sensitization about palliative care. It took almost a decade to let community accept the fact that palliative care is an integral part of healthcare. Even now there are millions who are not aware about the palliative care and hospice and our aim is to reach each needy at the right time.

Impact

Over the years, **14,000+** souls have found a peaceful farewell in the compassionate embrace of Sparsh, and **52,000+** families have received guidance, strength, and cherished memories that last a lifetime. Each story reminds that love, dignity, and compassion are the greatest gifts we can offer.

Together, we can continue to spread hope, comfort, and dignity because at Sparsh, every life matters, and every goodbye deserves to be beautiful.

www.sparshhospice.org/

Conact: Radhika Kancherla Operations Head 7995027880

Process Validation: The Life Cycle Approach

Dr. Ajay Babu Pazhayattil

In 2011, the US FDA revised the Process Validation (PV) Guidance [1], marking a substantial conceptual shift. The framework applies equally to API/drug substance producers as well as to drug product manufacturers. Since its release, regulatory observations citing inadequate PV implementation have surged for both drug substance and drug product sectors, making it a persistent high-risk compliance area. In fact, applying the new PV concepts to drug substance manufacturing is more challenging, as the processes are inherently more complex and endpoint-based, making them far more difficult to control. Despite many subject matter experts entering and leaving the field, one truth has remained consistent: regulators expect companies to adopt the life cycle approach in practice or be prepared for recurring observations. The perspectives discussed are based on my direct contributions to all major industry guidelines related to PV (AAPS, ISPE, PDA, RAPS), a unique opportunity I have been fortunate to have [2, 3, 4, 5, 6]. If you are committed to transforming your approach to process validation, I invite you to read on.

Under the life cycle approach, process validation is no longer a finite activity conducted prior to commercialization. Instead, it is an ongoing exercise where a process is always in one of three stages [Table 1]

Table 1: Pre and Post 2011

Process Validation- In the Past	***Process Validation- Today***
Process Qualification Only (Similar to Today's Stage 2- PPQ)	Process Design (Stage 1- QbD) + Process Performance Qualification (Stage 2- PPQ) + Continued Process Verification (Stage 3- CPV)

In the past, PV largely ended with a singleton stage of running 3 batches with additional sampling and testing. Today, it is a continual cycle [Figure 1]. The newer Stage 3 introduces perpetual oversight, meaning your process will re-enter Stage 1 whenever statistical alerts or drift are detected. The shift requires far more rigorous process design. Scale-up factors and their impact on critical quality attributes (CQAs) must be understood up front. Without identifying the sources of variability and their magnitudes, achieving the required statistical confidence during Stage 3 becomes difficult. When a process is in Stage 3 CPV, a statistical alert and resultant analysis may result in returning to Stage 1. Conversely, processes with low inherent variability are more likely to meet Stage 3 criteria without any remediation. This connection has driven companies to invest heavily in Design of Experiments (DoE) and in mapping the influence of process parameters on CQAs early in development. Armed with Stage 1 insights, the development teams can best

estimate the number of Stage 2- PPQ batches required [7], justify the sampling plans, and testing needed to statistically prove process robustness. This informed Stage 2 execution increases the likelihood of seamless progression into Stage 3- CPV.

Figure 1: The Cycle of Process Validation



When Stage 2 PPQ concludes, many organizations jump straight to routine Stage 3 monitoring. In 2014, we proposed an intermediate Stage 3a [8], which is a targeted, protocol-driven, heightened monitoring phase. Stage 3a is aimed at confirming that the process behaves as predicted during QbD based development [9]. It involves close monitoring of a substantial number of commercial batches under intensified sampling and the use of advanced statistical tools for analysis [10]. Stable parameters with minimal impact on CQAs can thus be eliminated from routine monitoring. The outcome is a detailed, scientifically sound, and statistically substantiated report that captures the most comprehensive understanding of the process and determines ongoing monitoring requirements.

Figure 2: Data Enablers for Stage 3 CPV



Stage 3b is the ongoing, SOP-driven phase of process monitoring and trending. It detects early signals of process drift and triggers escalation where necessary prior to a failure. Effective Stage 3b execution primarily requires an integrated electronic data system that consolidates process

parameters from equipment and instruments, quality attribute data from LIMS or similar solutions, quality events information from QMS, and material/batch information from ERP systems [Figure 2]. Change management under the life cycle approach demands a different mindset as well. Any change affecting a process in Stage 3 requires a return to Stage 1 for evaluation/process redesign. A process in Stage 3 never moves directly back to Stage 2 PPQ without first revisiting Stage 1. Since a transition always requires the active involvement of the process development team, and the Stage 3a assessment, as well as Stage 3b signals, need regular input from the same group, it is advisable to shift process validation responsibility from the traditional quality or operations teams to the site's technical operations or process development groups.

Many may question whether the additional effort and cost are justified. The greatest advantage of fully embracing PV expectations is a dramatic reduction in failures. With a deep understanding and control of variability, the risk of process failures becomes minimal. Combined with early detection of process drift, the lifecycle approach to PV ensures consistently smooth and reliable operations. The resulting decrease in failures and enhanced operational stability translates into significant financial benefits often exceeding those achieved through conventional lean methods. The implementation enables greater flexibility in managing changes because their effects are predictable and quantifiable, leading to substantially lower change management costs. Lastly, organizations that fully implement the process validation lifecycle approach are viewed by regulators as mature and reliable, which greatly reduces the likelihood of enforcement actions.

References:

1. *US FDA Guidance for Industry: Process Validation* www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf
2. *AAPS Solid Oral Dose Process Validation- The Basics* https://link.springer.com/book/10.1007/978-3-030-02472-7
3. *AAPS Solid Oral Dose Process Validation- Lifecycle Approach Application* https://link.springer.com/book/10.1007/978-3-030-27484-9
4. *RAPS Fundamentals of EU Regulatory Affairs*
5. *ISPE Good Practice Guide: Process Validation* https://ispe.org/publications/guidance-documents/good-practice-guide-process-validation
6. *Pazhayattil, A. (2020). Continued Process Verification: Reacting to Data Signals, PDA* https://www.pda.org/pda-letter-portal/home/full-article/continued-process-verification-reacting-to-data-signals
7. *Pazhayattil, A., Alsmeyer, D., Chen, S., Hye, M., Ingram, M., Sanghvi, P. (2015). A Scientific Approach to Determine the Number of PPQ Batches, AAPS PharmSciTech* https://pubmed.ncbi.nlm.nih.gov/26349690/
8. *Alsmeyer, D., Pazhayattil, A. (2014). A Case for Stage 3 Continued Process Verification, Pharmaceutical Manufacturing* https://www.pharmamanufacturing.com/compliance/validation/article/11325004/a-case-for-stage-3-continued-process-verification

9. *Sayeed, N., Pazhayattil, A., Collins, J., Chen, S., Ingram, M., Spes, J. (2016). Assessment Methodology for Process Validation Lifecycle Stage 3a, AAPS PharmSciTech* https://pubmed.ncbi.nlm.nih.gov/27714700/
10. *Alsmeyer, D., Pazhayattil, A., Chen, S., Munaretto, F., Hye, M., Sanghvi, P. (2015). Acceptance Probability (Pa) Analysis for PV Lifecycle Stages, AAPS PharmSciTech* https://pubmed.ncbi.nlm.nih.gov/26024723/

How AI Is Addressing Drug Development Challenges in Rare Diseases?

Kate Williamson, Editorial Team, Pharma Focus Europe

Drug development for rare diseases that affect less than 0.1% of the population proves challenging because of restricted data availability and small patient numbers and high project expenses. Modern drug discovery alongside clinical trials and personalized medicine receive significant advancement through artificial intelligence (AI). This examination demonstrates how AI drug discovery deployments along with AI-powered platforms and machine learning algorithms and AI-derived insights tackle important restrictions for treating rare diseases while simultaneously lowering developmental costs and accelerating processes for precision medicine development.

Introduction:

Healthcare struggles with persistent obstacles to treat and understand rare diseases which societies call orphan diseases. While affecting a minority portion of individuals these rare diseases make therapy discovery difficult because of scarce research data and expensive evaluation costs alongside multifaceted disease pathways. The rising use of artificial intelligence (AI) drives a transformative change in drug development and it extends new hope to worldwide populations of millions of patients.

The execution of medical therapies could become faster through AI technology because pharmaceutical companies together with scientists will break past conventional research blockers.

The Challenge of Rare Diseases

Research indicates that worldwide there exist more than 7,000 rare conditions which impact millions of individuals throughout the world. However, only a small fraction have approved treatments due to challenges like:

- **Limited data availability:** Smaller samples of patients produce split data and unfulfilled research data.
- **High costs:** Pharmaceutical businesses frequently find developing pharmaceuticals for specific niche markets incapable of yielding financial success.
- **Time constraints:** Specific drug development methodologies spanning thirteen years frequently meet failure before approval.

The solution to pharmaceutical development challenges emerges through artificial intelligence because AI-powered platforms and machine learning algorithms rewrite traditional drug discovery methods.

1. Overcoming Limited Data Availability with AI

The development of rare disease therapies faces significant hurdles because of limited patient research information. Small population numbers create challenges for researchers to obtain datasets which are both meaningful enough and abundant enough. Research insights generated through artificial intelligence prove key to closing these information gaps.

Mining and Analyzing Data

Computer systems use their strong analytical abilities to process broken and missing datasets in order to generate useful information. Machine learning tools help detect recurring patterns between genetic data along with medical records and patient registries to provide researchers with more profound disease mechanism insights.

Real-World Applications

Healx and Insilico Medicine employ artificial intelligence platforms to alastra various information sources from which new therapeutic goals can be extracted. Device-driven drug discovery uses artificial intelligence to process small datasets that are essential for rare diseases research.

2. Accelerating Drug Discovery with AI-Based Tools

Artificial intelligence enhances drug treatment development through advancements which specifically target rare diseases. Traditional drug discovery techniques burden the process with excessive time requirements and demand substantial financial resources spread across numerous years of research. Drugs that employ artificial intelligence-based discovery components speed up the development process and lower its costs.

Key Advancements

- AI algorithms today examine billions of chemical compounds much faster than traditional methodologies need for completion.
- Researchers use predictive analytics to generate drug-target interaction models with exceptional precision.
- AI-powered platforms help healthcare teams distinguish top therapeutic compounds throughout initial testing stages.

Case Studies

AI technology at Atomwise and BenevolentAI helps pharmaceutical firms enable quick molecule searches for drugs that demonstrate therapeutic promise. By analyzing extensive datasets their algorithms generate predictions about which chemical compounds have better odds of becoming successful in preclinical testing to lower the possibility of experimental failure.

3. Personalized Medicine and AI-Driven Insights

Rare diseases demonstrate extensive genetic variations, so personalized medicine becomes the mandatory approach to treatment. The application of artificial intelligence enables personalized medical treatments that optimize recovery results for patients.

Precision Medicine Powered by AI

Machine learning systems study genomic information to detect genetic fault connections with uncommon medical conditions.

The combination of artificial intelligence platforms with power-based algorithms design drugs that specifically target mutational variances thus creating highly

effective therapeutic solutions.ng traditional methods.

Real-World Impact

The genetic research company Moderna and Genentech uses AI intelligence to create RNA treatments targeting rare genetic conditions. By implementing Artificial Intelligence technologies into their discovery process these organizations produce drugs specifically designed to eradicate essential disease origins.

4. Enhancing Clinical Trials with AI

The clinical trial process for rare diseases encounters distinctive difficulties when conducting research on small, isolated populations of patients. AI-powered platforms are addressing these issues by:

- The rapid identification of qualified patients occurs through predictive analytics systems.
- Advancing trial designs with operational efficiency as a principal objective.
- Real-time patient monitoring allows researchers to minimize dropout numbers.

Optimizing Trial Success

Artificial intelligence in drug discovery provides researchers with capabilities to predict how patients will respond to treatments allowing protocol refinement. Predictive analysis through artificial intelligence creates trial design improvements which boost success rates although studies conduct operations with minimum patient involvement.

5. Reducing Costs in Drug Development

Pharmaceutical firms avoid selecting rare disease development due to its high budget requirements. AI-based drug discovery tools are changing this by:

The pharmaceutical industry benefits from automated processes which manage compound screening and preclinical testing tasks that require multiple workers. Early detection of potential failures enables the prevention of expensive problems which occur during later development stages.

Cost-Effective Solutions

Artificial intelligence platforms enable pharmaceutical companies to decrease development expenses thus improving their financial viability for rare disease medicines. Through AI algorithms Recursion Pharmaceuticals automates cell imaging procedures while compound identification reduces research spending.

Conclusion:

The use of artificial intelligence represents a revolutionary step for advancing drug discoveries which aim to fight rare diseases. Using platform technology alongside machine learning algorithms and AI-driven evaluations enables researchers alongside pharmaceutical companies to tackle major issues within their field. The current healthcare industry is undergoing major change because AI-based drug discovery tools help researchers overcome data restrictions while lowering costs and enabling customized medical solutions.

With advancements in technology the future applications of artificial intelligence for complex rare disease solutions will become increasingly vital. The strategy brings hope to countless patients alongside firm declarations that any disease should receive needed attention. When we use AI in drug discovery we create new possibilities that lead to a future where medical evolution combines with empathetic medical practices to offer every patient opportunity for improved health outcomes.

Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

8th Edition of Industrial Green Chemistry World (IGCW-20250 Convention & Expo
6-8th October 20205 Hotel Westin, Garden City, Mumbai

This flagship biennial event, organised by **Green ChemisTree Foundation** in collaboration with the **Dept. of Chemicals & Petrochemicals**, Govt. of India; and with support from **Maharashtra Pollution Control Board** (MPCB) and the **Ministry of Environment, Forests & Climate Change** (MoEFCC), offers a powerful industry-led platform to explore and accelerate green and sustainable chemistry innovations across India's chemical and allied sectors.

What to Expect at IGCW-2025?

- **10 Parallel Technical Sessions** over two days
- **100+ Subject-experts from Industry & Academia**
- Case studies, success stories & practical insights
- **IGCW-EXPO** showcasing ready-to-implement technologies
- **Unparalleled networking** with decision-makers across R&D, EHS, Manufacturing, Regulatory & Policy

Technical Sessions:

1. Green Chemistry Tools for Process Research
2. Sustainability & Green Chemistry Metrics
3. Facilitating Industrial Sustainability & Pollution Prevention (for PCBs)
4. Environment, Health & Safety – Tools & Technologies
5. Renewable Feedstocks for Sustainability
6. Chemo-Catalysis for Sustainability
7. Bio-catalysis: A Powerful Tool
8. Green Engineering for Process Safety & Benign Environment
9. Waste Valorization & Industrial Ecology
10. Software & Analytical Tools for Green Chemistry

For more details, download **IGCW-2025 Brochure.** For Registration, please visit: https://www.industrialgreenchem.com/registration. For group participation please call Mr. Amardeep Gagat at 8452894472 OR Ms. Krishna Padia 9920333228.

Registration: Rgtd. No. RD/S.25 (I) /STA/19/10/5342
C/o. Newreka *Green Synth* Technologies Pvt. Ltd., 405, Mastermind IV, Nr. Royal Palms, Aarey Colony, Goregaon (East), Mumbai - 65, Maharashtra, India.
Tel. : +91-22-28791835 / 1275 | Fax : +91-22-28794790 | Email : connect@greenchemistree.co.in | connect@industrialgreenchem.com
www.greenchemistree.co.in | www.industrialgreenchem.com

GLOBAL PHARMA HEALTHCARE PVT LTD

CHENNAI www.global-pharma.com; 44 2472 6001

RECRUITMENT

We are looking for:

- 15 -20 male fresh candidates with ITI / Diploma / B.Sc (Chemistry) / B.Tech
- 5 male candidates with 2-5 years working experience in any API industry
-

For our API Plant located in Kanchipuram, Tamil Nadu to work in Production and other related departments. Necessary training will be provided to the fresh candidates.

We are open to offering **2–3 year contracts** for suitable candidates who are willing to relocate to Kanchipuram. Compensation will be aligned with **prevailing market salary standards**, along with necessary support for settling and working in the facility.

Interested candidates may contact

Mr. R Surya; 7448788759; global.cheyyar@global-pharma.com within 15 days.

Important Note:

The organizers of Global ChemiShow offered 30 stalls (fully furnished 9 sq. meter stalls) on Complimentary basis. 12 of our members have already taken the Stalls. Members who are interested to avail these FREE stalls, please write to ed@bdmai.org ; info@bdmai.org; Stalls will be allotted on first-come-first-serve basis.

Executive Committee of

BULK DRUG MANUFACTURERS ASSOCIATION OF INDIA

Cordially Invites all Members of the Association

for the

34th Annual General Meeting

Date: Thursday, 18th September 2025
Time: 6.30 p.m. (followed by cocktail dinner)
Venue: 'Hyder Mahal', ITC Grand Kakatiya, Begumpet, Hyderabad

***

Programme

(After AGM)

Fireside Chat with

Sri G V Prasad

Co-Chairman & MD
Dr. Reddy's Laboratories Ltd

A brief Presentation on

'Harnessing solar -Advancing Pharma Industry'

By Anor Sunshine, A Solar Company

A brief Presentation on

'Sustainable Energy Transition Solutions for Pharma Industry'

By Sri Edwin Franklin
Corporate Regional Head, Thermax Limited

L V SUNIL
GENERAL SECRETARY

R K AGRAWAL
NATIONAL PRESIDENT